[go: up one dir, main page]

MX2017012982A - Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. - Google Patents

Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.

Info

Publication number
MX2017012982A
MX2017012982A MX2017012982A MX2017012982A MX2017012982A MX 2017012982 A MX2017012982 A MX 2017012982A MX 2017012982 A MX2017012982 A MX 2017012982A MX 2017012982 A MX2017012982 A MX 2017012982A MX 2017012982 A MX2017012982 A MX 2017012982A
Authority
MX
Mexico
Prior art keywords
cells
compositions
methods
immunomodulatory
monocytes
Prior art date
Application number
MX2017012982A
Other languages
English (en)
Other versions
MX386896B (es
Inventor
w andrews David
C Hopper Douglas
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of MX2017012982A publication Critical patent/MX2017012982A/es
Publication of MX386896B publication Critical patent/MX386896B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación provee composiciones farmacóuticas que comprenden ácidos nucleicos capaces de hacer blanco en la expresión de IGF-1R en las cólulas M2; la presente divulgación también provee métodos para la reducción selectiva de cólulas M2 haciendo blanco en la expresión de IGF-1R en estas cólulas; la presente divulgación provee, además, métodos para el tratamiento del cáncer y mejoramiento terapóutico haciendo blanco en la expresión de IGF-1R en cólulas M2 en los pacientes; la composición farmacóutica de la presente invención es eficaz cuando se le administra sistómicamente a los sujetos que la necesitan; la facilidad de administración de la composición farmacóutica facilita el tratamiento y mejora el cumplimiento del paciente.
MX2017012982A 2015-04-10 2016-04-11 Composiciones y el uso de las mismas para incrementar la inmunidad terapéutica reduciendo selectivamente los monocitos m2 inmunomoduladores. MX386896B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562145758P 2015-04-10 2015-04-10
PCT/US2016/026970 WO2016164916A1 (en) 2015-04-10 2016-04-11 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes

Publications (2)

Publication Number Publication Date
MX2017012982A true MX2017012982A (es) 2018-07-06
MX386896B MX386896B (es) 2025-03-19

Family

ID=57072956

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012982A MX386896B (es) 2015-04-10 2016-04-11 Composiciones y el uso de las mismas para incrementar la inmunidad terapéutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
MX2021012272A MX2021012272A (es) 2015-04-10 2017-10-09 Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012272A MX2021012272A (es) 2015-04-10 2017-10-09 Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.

Country Status (8)

Country Link
US (6) US10206942B2 (es)
EP (1) EP3280806A4 (es)
JP (3) JP6957035B2 (es)
CN (1) CN108260357A (es)
AU (3) AU2016246134B2 (es)
CA (1) CA2982205A1 (es)
MX (2) MX386896B (es)
WO (1) WO2016164916A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164916A1 (en) 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
SG11201802718PA (en) 2015-10-14 2018-05-30 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
CA3034637A1 (en) 2016-09-16 2018-03-22 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
JP2020508355A (ja) * 2017-02-24 2020-03-19 トーマス・ジェファーソン・ユニバーシティ 腫瘍成長を阻害し且つ腫瘍に対する免疫反応を増強するための方法及び組成物
CN110832068A (zh) 2017-03-09 2020-02-21 托马斯杰弗逊大学 使用反义分子治疗癌症的方法和组合物
AU2018255353B2 (en) * 2017-04-19 2023-11-16 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for IGF-1R inhibition
WO2018195281A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
EP3612159A4 (en) 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION
KR102775924B1 (ko) 2017-04-19 2025-03-07 바이오-패쓰 홀딩스 인크. Bcl2 억제용 p-에톡시 핵산
WO2019014511A2 (en) * 2017-07-14 2019-01-17 Minzhen Xu METHOD FOR INDUCING AN IMMUNE RESPONSE DOMINATED BY M1 AND PHARMACEUTICAL COMPOSITIONS
GB201714330D0 (en) 2017-09-06 2017-10-18 Järver Peter Oligonucleotides
KR102802097B1 (ko) * 2018-01-24 2025-04-29 토마스 제퍼슨 유니버시티 생물확산 챔버
US20220000916A1 (en) * 2018-11-02 2022-01-06 Thomas Jefferson University Methods and compositions for treating breast cancer using antisense
AU2019374061A1 (en) * 2018-11-02 2021-06-03 Thomas Jefferson University Methods and compositions for treating hepatocellular carcinoma using antisense
US20220195440A1 (en) * 2019-03-28 2022-06-23 Thomas Jefferson University Methods for treating cancers using antisense
USD1107915S1 (en) 2019-07-23 2025-12-30 Thomas Jefferson University Biodiffusion chamber

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK114394B (da) 1963-06-17 1969-06-23 O Hoyer Fremgangsmåde ved emballering af aflange formlegemer, navnlig ispinde, samt maskine til udøvelse af fremgangsmåden.
US3331526A (en) 1964-07-20 1967-07-18 Levenson Leonard Lionel Ultrahigh vacuum seal
US3270877A (en) 1965-06-18 1966-09-06 Hanns E Hecker Package for columnar articles
US3589511A (en) 1969-08-13 1971-06-29 Owens Illinois Inc Package and tray for tubes or the like
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
EP0247730A3 (en) 1986-04-28 1989-04-12 Antibody Technology Limited Antibodies, their preparation and use and products containing them
US5167638A (en) 1989-10-27 1992-12-01 C. R. Bard, Inc. Subcutaneous multiple-access port
US5834005A (en) 1992-02-24 1998-11-10 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
WO1994022486A1 (en) 1993-03-26 1994-10-13 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5714170A (en) 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6218519B1 (en) 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
CA2264227A1 (en) 1996-09-27 1998-04-02 Raymond A. Firestone Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6071891A (en) 1996-11-22 2000-06-06 Regents Of The University Of Minnesota Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
US6541036B1 (en) 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
EP1080732A4 (en) 1998-05-22 2004-08-25 Daiichi Seiyaku Co DRUG COMPOSITION
WO2000009145A1 (en) * 1998-08-13 2000-02-24 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6144553A (en) 1998-09-09 2000-11-07 Sun Microsystems, Inc. Refrigeration cooled disk storage assembly
US6268488B1 (en) 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
IL134009A (en) 2000-01-12 2011-07-31 Bo2 Technologies Ltd Transplant device
US20040052793A1 (en) 2001-02-22 2004-03-18 Carter Paul J. Caspase activivated prodrugs therapy
US6773897B2 (en) 2000-09-29 2004-08-10 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
AU2002363939A1 (en) 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
EP1575514A2 (en) 2002-07-31 2005-09-21 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
AU2003256038A1 (en) 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US7037335B2 (en) 2002-11-19 2006-05-02 Eagle Vision, Inc. Bulbous scleral implants for the treatment of eye disorders such as presbyopia and glaucoma
CA2515484C (en) 2003-02-11 2011-09-20 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7846906B2 (en) 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CA2447400A1 (en) 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
NZ594834A (en) 2003-12-16 2013-03-28 Nektar Therapeutics Method of preparing PEGylated protein molecules
US20050288491A1 (en) 2004-02-17 2005-12-29 Wilson David S Super-humanized antibodies against respiratory syncytial virus
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
JP2008519584A (ja) 2004-11-09 2008-06-12 シェーリング コーポレイション 患者のｍｇｍｔレベルに基づいて癌を処置するための、テモゾロミドの改良された投薬養生法
WO2006082406A2 (en) 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
EP1900825A1 (en) 2006-09-13 2008-03-19 Rheinische Friedrich-Wilhelms-Universität Bonn Sensitive and reproducible method for the determination of MGMT promoter methylation in clinical samples
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
FI123146B (fi) 2009-10-01 2012-11-30 Bayer Schering Pharma Oy Kohdunsisäinen järjestelmä
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP5875083B2 (ja) 2010-04-15 2016-03-02 メディミューン リミテッド 増殖性疾患治療用ピロロベンゾジアゼピン
WO2011130615A2 (en) 2010-04-15 2011-10-20 Dr. Reddy's Laboratories Ltd. Preparation of lacosamide
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
AU2011239522B2 (en) 2010-04-15 2014-10-23 Medimmune Limited Targeted pyrrolobenzodiazapine conjugates
WO2011154941A2 (en) 2010-06-07 2011-12-15 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
AU2011307663B2 (en) 2010-09-27 2015-05-07 Gloriana Therapeutics Sarl Implantable cell device with supportive and radial diffusive scaffolding
KR101913232B1 (ko) 2010-10-27 2018-10-30 큐알엔에이, 인크. 인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료
EP2567905A1 (en) 2011-09-09 2013-03-13 Becton Dickinson France Tray and packaging for medical containers
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
CN102898426B (zh) * 2012-11-15 2015-04-22 江苏先声药业有限公司 抑制igf-1r酪氨酸激酶活性的吡啶并吡唑类衍生物
US9950149B2 (en) 2013-04-24 2018-04-24 Nestec S.A. Biomolecular cell encapsulation device and methods of implantation
US9539757B2 (en) 2013-06-26 2017-01-10 Tekni-Plex, Inc. Packing tray having cell pockets with expandable sidewalls and floating base, and method of manufacture
US20160220692A1 (en) 2013-09-09 2016-08-04 The Johns Hopkins University Targeting the m2-tumor associated macrophage for cancer therapy
KR102323291B1 (ko) 2013-09-24 2021-11-05 기너 라이프 사이언시즈, 인크. 세포 임플란트의 기체 처리를 위한 시스템
DK3013986T3 (en) 2014-01-03 2017-02-27 Koninklijke Philips Nv ASSESSMENT OF PI3K CELL SIGNALING ACTIVITY ACTIVITIES USING MATHEMATICAL MODELING OF TARGET EXPRESSION
US9872674B2 (en) 2014-05-07 2018-01-23 Boehringer Laboratories Inc. Entrapment and containment system for use with a morcellator and method of entrapping and containing material produced during morcellation procedure
WO2016164916A1 (en) 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
EP3285664B1 (en) 2015-04-23 2021-08-04 Applied Medical Resources Corporation Systems for tissue removal
PT3313884T (pt) 2015-06-29 2021-02-25 Immunogen Inc Anticorpos anti-cd123 e conjugados e derivados dos mesmos
SG11201802718PA (en) 2015-10-14 2018-05-30 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
CN110832068A (zh) * 2017-03-09 2020-02-21 托马斯杰弗逊大学 使用反义分子治疗癌症的方法和组合物
WO2018195281A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
KR102802097B1 (ko) 2018-01-24 2025-04-29 토마스 제퍼슨 유니버시티 생물확산 챔버
EP4031465B1 (en) 2019-09-19 2026-01-28 Thomas Jefferson University Apparatus and methods for biodiffusion chamber storage
MX2022011532A (es) 2020-03-18 2022-10-13 Takeda Pharmaceuticals Co Dispositivo de camara celular implantable y usos de este.
CA3179703A1 (en) 2020-04-09 2021-10-14 Defymed Membranes for medical devices

Also Published As

Publication number Publication date
US10206942B2 (en) 2019-02-19
US11077133B2 (en) 2021-08-03
US10543226B2 (en) 2020-01-28
EP3280806A4 (en) 2018-12-05
AU2022206776A1 (en) 2022-09-15
US20220072025A1 (en) 2022-03-10
EP3280806A1 (en) 2018-02-14
JP2021193143A (ja) 2021-12-23
US20200197435A1 (en) 2020-06-25
US20170056430A1 (en) 2017-03-02
JP2018515598A (ja) 2018-06-14
US20250009781A1 (en) 2025-01-09
US20180235996A1 (en) 2018-08-23
AU2016246134A1 (en) 2017-11-02
MX386896B (es) 2025-03-19
CN108260357A (zh) 2018-07-06
US10265339B2 (en) 2019-04-23
JP2024028529A (ja) 2024-03-04
MX2021012272A (es) 2021-11-12
AU2022206776B2 (en) 2025-05-08
JP6957035B2 (ja) 2021-11-02
US20180271894A1 (en) 2018-09-27
JP7428397B2 (ja) 2024-02-06
AU2025202730A1 (en) 2025-05-08
CA2982205A1 (en) 2016-10-13
AU2016246134B2 (en) 2022-04-21
US12064446B2 (en) 2024-08-20
WO2016164916A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
MX2017012982A (es) Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
MY188139A (en) Sodium channel modulators for the treatment of pain
MX2017000080A (es) Conjugados y particulas direccionados y formulaciones de estos.
MX2018004177A (es) Terapia de combinacion para el tratamiento de cancer.
MX381475B (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MX391720B (es) Terapia combinada para tratar cáncer.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
MX2019003134A (es) Terapia de combinacion.
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
EA201792256A1 (ru) Соли и пролекарства 1-метил-d-триптофана
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
BR112018002530A2 (pt) combinações e usos e tratamentos destas
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
EA201691964A1 (ru) Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.